MBOT logo

MICROBOT MEDICAL INC

MBOTNASDAQ
๐Ÿ† #4222 by market capEarnings Mar 24 ยท PostUS Equity
$0.68โ–ผ $0.07 (โˆ’9.10%)
Market closed ยท at close
๐Ÿ””
Track MBOT
Get earnings, price moves & breaking news on Telegram
Track
24hโ–ผ 9.1%
7dโ–ผ 30.3%
14dโ–ผ 39.5%
30dโ–ผ 30.3%
ytdโ–ผ 66.1%
1yโ–ผ 62.9%
๐ŸฆMarket Cap
$46M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
โ€”
๐Ÿ“ŠGross Margin
-185.3%
Thin
๐Ÿ’ตFCF Margin
6933.5%
Strong
โš–๏ธP/S Ratio
132.0x
Expensive
Otter Score
โ€”
Insufficient data

Trading Snapshot

Day Range
$0.66 โ€“ $0.74
52-Week Range
$0.52 โ€“ $2.86
Volume (shares)
24,826
Avg Volume (shares)
โ€”
Shares Outstanding
67.2M
Next Earnings
2027-03-24

Fundamentals Snapshot

Annual Revenue
โ€”
Last Q Revenue
โ€”
P/E Ratio
โ€”
P/S Ratio
132.0x
EPS (TTM)
$-0.26
Dividend Yield
โ€”
MBOT logo

MICROBOT MEDICAL INC

MBOT
Financial Trends

Financial history unavailable.

StockOtter ยท stockotter.space

About MICROBOT MEDICAL INC

Microbot Medical Inc. operates as a pre-clinical stage medical device company, concentrating its efforts on the research, design, and development of robotic instruments for endoluminal surgery, specifically targeting the field of minimally invasive procedures. Leveraging its proprietary micro-robotic technologies, which include ViRob, TipCAT, CardioSert, and Liberty, the company is actively developing several key products. These include a Self-Cleaning Shunt intended for the treatment of hydrocephalus and normal pressure hydrocephalus, as well as a single-use robotic system designed for various endovascular interventional applications. Additionally, Microbot Medical maintains a robust, multi-generational product pipeline. Its global intellectual property portfolio is substantial, encompassing 42 granted or allowed patents and an additional 23 patent applications currently under review. The company also benefits from a strategic collaboration agreement with Stryker Corporation, focusing on joint technology development. Established in 2010, Microbot Medical Inc. is headquartered in Hingham, Massachusetts.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Insufficient data
โ€”/100

Analyst Ratings

โ“˜
Consensus
Buy
10 analysts
Strong Buy2
Buy7
Hold1
Sell0
Strong Sell0
Ratings as of Nov 2026

Latest News & Updates

News unavailable.